Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Change in Accured Expenses for 17 consecutive years, with $71.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 113.88% year-over-year to $71.3 million; the TTM figure through Jun 2026 stood at $174.7 million (up 317.16% YoY), while the FY2025 annual figure was $131.9 million, up 279.96% from the prior year.
• Change in Accured Expenses climbed to $71.3 million in Q2 2026 per MDGL's latest filing, from $4.3 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $187.5 million in Q3 2025 and bottomed at -$88.4 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged $15.4 million across 5 years, with a median of $5.8 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Accured Expenses jumped 1712.96% — and 2025, when it tumbled 1301.7%.
• Madrigal Pharmaceuticals' Change in Accured Expenses stood at $11.9 million in 2022, then sank by 37.87% to $7.4 million in 2023, then tumbled by 185.59% to -$6.3 million in 2024, then sank by 1301.7% to -$88.4 million in 2025, then jumped by 180.59% to $71.3 million in 2026.
• Business Quant data shows MDGL's Change in Accured Expenses at $71.3 million in Q2 2026, $4.3 million in Q1 2026, and -$88.4 million in Q4 2025.